Patent foramen ovale closure with the Occlutech Figulla flex II device: A long-term (up to 10-years) follow-up

Int J Cardiol

24 July Jul 2023 11 months ago
  • Trabattoni D, Gili S, Calligaris G, Teruzzi G, Troiano S, Ravagnani P, Baldi GS, Montorsi P

Percutaneous closure represents the first line of treatment in patients with cryptogenic stroke and documented patent foramen ovale (PFO). Scarce data report the long-term outcomes of patients undergoing PFO closure with the Figulla Flex II device (Occlutech, Germany).

Reference: Patent foramen ovale closure with the Occlutech Figulla flex II device: A long-term (up to 10-years) follow-up.
Trabattoni D, Gili S, Calligaris G, Teruzzi G, Troiano S, Ravagnani P, Baldi GS, Montorsi P. Int J Cardiol. 2023 Jun 8:S0167-5273(23)00882-3.

Go to PubMed